Búsqueda de Publicación - Prisma - Unidad de Bibliometría

Publicaciones en la fuente EUROPEAN NEUROPSYCHOPHARMACOLOGY

Tipo Año Título Fuente
Artículo2024Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up studyEUROPEAN NEUROPSYCHOPHARMACOLOGY
Revisión2024Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practiceEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2024Shared vulnerability and sex-dependent polygenic burden in psychotic disordersEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2023The longitudinal trajectory of emotional cognition in subgroups of recently diagnosed patients with bipolar disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2023The polygenic basis of relapse after a first episode of schizophreniaEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2022Association of childhood trauma exposure with DDR1 promoter methylation in bipolar disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2022Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosisEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2021Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: a 6-week randomized, flexible-dose, open-label clinical trialEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2021Classification of first-episode psychosis using cortical thickness: A large multicenter MRI studyEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2021Emotional cognition subgroups in mood disorders: Associations with familial riskEUROPEAN NEUROPSYCHOPHARMACOLOGY
Nota2021Social cognition in bipolar disorder: A proxy of psychosocial function and novel treatment target?EUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2020A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patientsEUROPEAN NEUROPSYCHOPHARMACOLOGY
Revisión2020The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harmsEUROPEAN NEUROPSYCHOPHARMACOLOGY
Revisión2019Behavioral addictions in bipolar disorders: A systematic reviewEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2019The impact of neurocognition on emotional intelligence in euthymic patients with bipolar disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2018Characterizing decision-making and reward processing in bipolar disorder: A cluster analysisEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2018The dynamic relationship between insight and suicidal behavior in first episode psychosis patients over 3-year follow-upEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2017A study on the bioequivalence of lithium and valproate salivary and blood levels in the treatment of bipolar disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2017Are there differences in the antipsychotic load between deficit and non-deficit syndrome in first-episode schizophrenia?EUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2017Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up studyEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2017Intra-cortical myelination during adolescence: linking MRI networks with gene transcription profilesEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2017Social cognition in bipolar disorder: exploring emotional intelligenceEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2016The possible resilience role of cognitive reserve in bipolar disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2015AMP-activated protein kinase is implicated in depressive behaviourEUROPEAN NEUROPSYCHOPHARMACOLOGY
Resumen congreso2015Bioequivalence of blood and salivary levels of lithium and valproate: Implications for the clinical management of bipolar disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2015Effectiveness of audiovisual campaigns against the stigmatisation of schizophreniaEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2015NLRP3-inflammasome complex is implicated in depressive behaviour induced by stressEUROPEAN NEUROPSYCHOPHARMACOLOGY
Artículo2015Suicidal behaviour in first-episode non-affective psychosis: Specific risk periods and stage-related factorsEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2014Inflammasome complex is implicated in the severity of major depressive disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2013Sociodemographic and clinical characteristics of involuntary admissions in patients with schizophrenia and bipolar disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2012How does amitriptyline treatment affect coenzyme Q levels and oxidative stress in patients diagnosed with depressive disorder?EUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2011Cytokines in patients with fibromyalgia illness and anxious-depressive symptomsEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2011The course of comorbid bipolar illness and alcoholic dependenceEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2011Treatment effects of atypical versus conventional long-acting injectable antipsychotics in a 60-month follow-up and subsequent extension studyEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2010Long-acting risperidone injection versus conventional depots in chronic psychotic patients: a 54 months studyEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2010Outcome of bipolar illness and comorbid personality disorderEUROPEAN NEUROPSYCHOPHARMACOLOGY
Ponencia2009Improved trophic efficacy of glial cell-derived neurotropic factor (GDNF) after combination with TGF-beta 1 both in vitro and in vivo models of parkinsonismEUROPEAN NEUROPSYCHOPHARMACOLOGY